Blog
RSS FeedPosted by Michael Wonder on 13 Oct 2020
PMV Pharma granted FDA fast track designation of PC14586 for the treatment of advanced cancer patients that have tumours with a p53 Y220C mutation
13 October 2020 - PMV Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to its lead product ...
Posted by Michael Wonder on 13 Oct 2020
Top Democrats call for watchdog to review Trump Medicare drug cards
13 October 2020 - Top-ranking Democrats want an independent watchdog to expedite a review of the Trump administration's plans to ...
Posted by Michael Wonder on 13 Oct 2020
Oxular receives rare paediatric disease and orphan drug designations for retinoblastoma treatment
12 October 2020 - Provides furthered momentum for OXU-003 development programme. ...
Posted by Michael Wonder on 13 Oct 2020
Stage 2 PBS process improvements – consultation closed
13 October 2020 - On 21 September 2020, the department hosted a webinar to provide information to industry on the ...
Posted by Michael Wonder on 12 Oct 2020
EMA publishes agenda for 12-15 October CHMP meeting
12 October 2020 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 12 Oct 2020
SMC accepts Bavencio (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
12 October 2020 - Merck and Pfizer announced today that the Scottish Medicines Consortium has accepted the immunotherapy Bavencio (avelumab) for ...
Posted by Michael Wonder on 12 Oct 2020
Alexion receives FDA approval for new advanced formulation of Ultomiris (ravulizumab-cwvz) with significantly reduced infusion time
12 October 2020 - New 100 mg/mL formulation will reduce infusion time by approximately 60 percent, lessening the burden on patients. ...
Posted by Michael Wonder on 12 Oct 2020
SMC - October 2020 decisions
12 October 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 12 Oct 2020
NICE proposes simplifying how medicines and medical devices are selected for evaluation
12 October 2020 - As part of the work underway to review the methods and processes NICE uses to develop guidance ...
Posted by Michael Wonder on 12 Oct 2020
Innovent and Lilly jointly announce the NMPA granted marketing approval for Halpryza (rituximab injection) in China
9 October 2020 - Innovent Biologics and Eli Lilly and Company today jointly announce that Halpryza (rituximab injection), a recombinant human/murine ...
Posted by Michael Wonder on 12 Oct 2020
PHARMAC apologises for contraceptive pill shortages
10 October 2020 - Pharmac is apologising to thousands of women who will be forced to change oral contraceptives because ...
Posted by Michael Wonder on 12 Oct 2020
Ambrisentan, diazepam and dexamethasone new exchange groups
9 October 2020 - From November, ambrisentan 5 mg & 10 mg tablets, diazepam,10 mg tablets and dexamethasone 1 mg/mL ...
Posted by Michael Wonder on 12 Oct 2020
Radiopharmaceutical cancer treatment Lutathera now available to Ontario patients with midgut neuroendocrine tumours
8 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs. ...
Posted by Michael Wonder on 11 Oct 2020
Rapid qualitative evidence syntheses in health technology assessment: experiences, challenges, and lessons
9 October 2020 - Health care decision makers are increasingly demanding that health technology assessment is patient focused, and considers data ...
Posted by Michael Wonder on 11 Oct 2020
Can Trump really speed approval of COVID treatments?
10 October 2020 - In a five minute video posted to his Twitter account on Wednesday, President Trump stood in ...